Incyte Corp
NASDAQ:INCY
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
51.18
83.38
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Incyte Corp
Wall Street
Price Targets
INCY Price Targets Summary
Incyte Corp
According to Wall Street analysts, the average 1-year price target for
INCY
is 80.31 USD
with a low forecast of 52.52 USD and a high forecast of 105 USD.
INCY Last Price Targets
Incyte Corp
The latest public price target was made on Oct 30, 2024 by
Jay Olson
from
Oppenheimer
,
who expects
INCY
stock to
rise by 19%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Jay Olson
Oppenheimer
|
82
USD
Upside 19% |
1 month ago
Oct 30, 2024
|
Incyte price target raised to $82 from $81 at Oppenheimer
TheFly
|
|
Aaron Kessler
Seaport Global
|
200
USD
Upside 191% |
1 month ago
Oct 30, 2024
|
This Alphabet Analyst Turns Bullish; Here Are Top 5 Downgrades For Wednesday
Benzinga
|
David Lebowitz
Citigroup
|
97
USD
Upside 41% |
1 month ago
Oct 30, 2024
|
Incyte (INCY) PT Raised to $97 at Citi
StreetInsider
|
Tazeen Ahmad
Bank of America Securities
|
90
USD
Upside 31% |
1 month ago
Oct 29, 2024
|
BofA Securities Upgrades Incyte (INCY) to Buy
StreetInsider
|
Kelly Shi
Jefferies
|
84
USD
Upside 22% |
1 month ago
Oct 29, 2024
|
Incyte (INCY) PT Raised to $84 at Jefferies
StreetInsider
|
Andy Chen
Wolfe Research
|
84
USD
Upside 22% |
2 months ago
Sep 30, 2024
|
Wolfe Research starts Incyte at Outperform amid 'major push' in I&I
TheFly
|
|
Tazeen Ahmad
Bank of America Securities
|
68
USD
Downside 1% |
3 months ago
Sep 16, 2024
|
Incyte (INCY) PT Raised to $68 at BofA Securities
StreetInsider
|
Salveen Richter
Goldman Sachs
|
60
USD
Downside 13% |
3 months ago
Sep 16, 2024
|
Goldman Sachs Reiterates Neutral Rating on Incyte (INCY)
StreetInsider
|
|
David Lebowitz
Citigroup
|
92
USD
Upside 34% |
4 months ago
Aug 18, 2024
|
Incyte price target raised to $92 from $88 at Citi
TheFly
|
Brian Abrahams
RBC Capital
|
66
USD
Downside 4% |
4 months ago
Jul 31, 2024
|
Incyte price target raised to $66 from $61 at RBC Capital
TheFly
|
|
Jay Olson
Oppenheimer
|
81
USD
Upside 18% |
4 months ago
Jul 26, 2024
|
Incyte price target lowered to $81 from $84 at Oppenheimer
TheFly
|
Evan Seigerman
BMO Capital
|
48
USD
Downside 30% |
5 months ago
Jul 2, 2024
|
BMO Capital Downgrades Incyte (INCY) to Underperform
StreetInsider
|
James Shin
Deutsche Bank
|
55
USD
Downside 20% |
7 months ago
May 23, 2024
|
Incyte initiated with a Hold at Deutsche Bank
TheFly
|
|
Evan David Seigerman
BMO Capital
|
52
USD
Downside 24% |
7 months ago
Apr 30, 2024
|
Incyte (INCY) PT Lowered to $52 at BMO Capital
StreetInsider
|
Jasper Hellweg
Argus Research
|
70
USD
Upside 2% |
7 months ago
Apr 25, 2024
|
Incyte price target lowered to $70 from $80 at Argus
TheFly
|
Unknown Analyst
Cowen & Co.
|
100
USD
Upside 45% |
1 year ago
Feb 8, 2023
|
Cowen & Co. Maintains Outperform on Incyte, Raises Price Target to $100
Benzinga
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is INCY's stock price target?
Price Target
80.31
USD
According to Wall Street analysts, the average 1-year price target for
INCY
is 80.31 USD
with a low forecast of 52.52 USD and a high forecast of 105 USD.
What is Incyte Corp's Revenue forecast?
Projected CAGR
11%
For the last 8 years the
compound annual growth rate for
Incyte Corp's revenue is
22%.
The projected
CAGR
for the next 4 years is
11%.
What is Incyte Corp's Operating Income forecast?
Projected CAGR
32%
For the last 8 years the
compound annual growth rate for
Incyte Corp's operating income is
38%.
The projected
CAGR
for the next 4 years is
32%.
What is Incyte Corp's Net Income forecast?
Projected CAGR
31%
For the last 8 years the
compound annual growth rate for
Incyte Corp's net income is
76%.
The projected
CAGR
for the next 4 years is
31%.
You don't have any saved screeners yet
